A New Mouse Model for Charcot-Marie-Tooth (CMT2)

by | May 27, 2015 | 0 comments

JAX Logo_tag_color_2-5in_600dpi (1) (1)We were recently informed that The Jackson Laboratory (JAX, a nonprofit biomedical research institution headquartered in Bar Harbor, Maine) had taken delivery and will be distributing a newly generated CMT-related mouse model. The new model expresses mutant mitofusin 2, a mitochondrial membrane protein involved in mitochondrial fusion and regulation of vascular smooth muscle cell proliferation.

The creator of the mouse model, Dr. David Pleasure of the University of California at Davis designed the mouse so that researchers have the ability to specifically induce expression of the mutant gene in a tissue of interest. Dr. Pleasure said, “The heterozygous mouse, which expresses the mutant gene as a knockin in the Rosa locus, shows a mild foot deformity demonstrable by catwalk analysis, as well as an imbalance in muscle fiber types demonstrable by immunohistology and histochemistry. Initial histological analysis of tibial nerve failed to document obvious axon loss. The phenotype in these young adult mice is subtle.” This project was funded by HNF. We look forward to Dr. Pleasure publishing his work in due course. It may require additional work to push the characterization of the mouse further. We have made the mouse model available without license so that other researchers can use and evaluate it freely. We thank The Jackson Laboratory for their considerable assistance and willingness to distribute this mouse.

Additional information can be obtained at The Jackson Laboratory strain datasheet. Orders can be placed for this mouse strain today, and the first mouse should be ready to be shipped by the end of the year. The JAX mouse repository provides a variety of other mouse models relevant for CMT, and is actively seeking additional models. Please contact Mike Sasner at [email protected]

Learn more on this topic

Related Blog Posts

Targeting PMP22 in CMT1A Patients with Gene Duplication

In previous collaborative work with a group of investigators including Dr Rolf Renne from the University of Florida, Dr. Alex Murashov from East Carolina University and Dr. Lynn Hudson from the NIH-NINDS, we validated a microRNA known as miR29a as a reagent that corrected the expression level of PMP22 in rodent Schwann cells.

September is CMT Awareness Month

CMT awareness month is an entire month dedicated to building awareness, raising funds and finding a cure. The Hereditary Neuropathy Foundation (HNF) has committed to spend 30 days in September hosting local and national events, launching fundraisers, and spreading the word about the effects of Charcot-Marie-Tooth disease

Quality of Life and CMT Research

Did you know that 95% of clinical trials fail? There are multiple causes, most related to efficacy or safety, which obviously can be harmful and risky for patients. The risk-reward of enrolling in trials is a judgment call based on the devastating effects of disease related to quality of life (QoL) or life-threatening disease. With CMT, the risk-reward is more of a challenging question for many, as CMT in most cases is non-fatal.

Help us answer questions that your doctors and the CMT Research Community aren’t too sure about.

Did you know that you can become part of a community in therapy development and further research for all forms of CMT and inherited neuropathies? The mission of the Global Registry for Inherited neuropathies (GRIN) is to collect clinical and genetic information from patients with ALL forms of Charcot-Marie-Tooth (CMT) and other related rare and ultra rare inherited neuropathies.

Hot off the press

It seems like almost weekly there is another new publication on CMT with interesting basic biology. While an earlier “Hot off the press” highlighted the work of Cherry and co-workers at the University of Texas Southwestern Medical Center who showed show that neurons lacking a gene for rab7 result in neuropathy.

Join the conversation

Leave a Comment


Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news